Novo Nordisk Appoints Jamey Millar to Lead U.S. Operations
Novo Nordisk has appointed Jamey Millar as Executive Vice President of U.S. Operations, placing him at the helm of the company’s largest sales region. Joining the company in February 2026, Millar takes over leadership of the U.S. Business during a pivotal era for the pharmaceutical giant, specifically as it manages the commercial trajectory of its high-profile obesity and diabetes portfolio.
A Strategic Hire for the U.S. Market
Millar’s appointment comes at a time when access and predictability for patients are paramount. In recent communications, Millar has emphasized that for people living with obesity, access is deeply personal, citing the need for simpler ways for patients to start and remain on treatment. His role involves overseeing the complex intersection of commercial strategy, market access, and enterprise leadership within the United States.
Deep Industry Expertise and Proven Track Record
With over 30 years of experience across the pharmaceutical, payer, and distribution sectors, Millar is a recognized expert in US commercial launches and product life-cycle management. His career is defined by leadership in several large chronic disease launches, including:
- Asthma and COPD
- Major Depressive Disorder
- Targeted therapies in oncology and blood disorders
- Specialty therapeutics
Beyond product launches, Millar brings specialized knowledge in Gross-to-Net/Payer strategies and the integration of Direct-to-Consumer (DTC) strategies, which are critical for maintaining a competitive edge in the U.S. Healthcare landscape.
Professional Background and Career Trajectory
Before joining Novo Nordisk, Millar served as the CEO of Optum Specialty Holdings at UnitedHealth Group. During his tenure at UnitedHealth, he led Industry Relations, where he managed manufacturer contracts, wholesaler agreements, network pharmacy agreements, formulary management, and Optum Life Sciences.
Prior to his time at UnitedHealth, Millar spent 20 years at GlaxoSmithKline PLC. His leadership roles there included serving as the Vice President/General Manager of the US Oncology Business Unit and Senior Vice President of Managed Markets and Government Affairs. He began his professional journey with Procter & Gamble Pharmaceuticals, working in both the United Kingdom and the United States.
Key Takeaways: Jamey Millar’s Profile
- Current Role: Executive Vice President, US Operations at Novo Nordisk (Joined February 2026).
- Core Expertise: US commercial strategy, market access, and R&D/Commercial planning.
- Previous Leadership: CEO of Optum Specialty Holdings (UnitedHealth Group) and senior roles at GlaxoSmithKline PLC.
- Education: BA in English Literature from Hamilton College (1990).
- Base of Operations: Princeton, NJ.
Looking Ahead
As Novo Nordisk continues to scale its operations in the U.S., Millar’s deep understanding of payer strategies and manufacturer contracts will be essential. His focus on improving the patient experience and streamlining access to treatment suggests a strategy centered on sustainability and long-term patient adherence in the highly competitive obesity and chronic disease markets.